Eli Lilly to Buy AtaiBeckley for Initial $2.8 Billion
Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker’s recent buying spree.
The Source
TWSJ
Business
Energy & Utilities Roundup: Market Talk
TWSJ·1h ago·3 min read
Business
Abbott Laboratories Sales Rise on Diagnostics Growth
TWSJ·1h ago·3 min read
Business
U.S. Jobless Claims Unexpectedly Dropped Last Week
TWSJ·1h ago·3 min read
Sports
Messi’s Mission vs. Spanish Control: The World Cup Final Is Set
TWSJ·1h ago·3 min read
Related
On this beat
Health
The FDA approved Lipfendra, a first-of-its kind pill from Merck that is designed to help lower cholesterol levels beyond what statins alone can achieve
TWSJ·3h ago·3 min read
Health
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
CNBC·3h ago·3 min read
Health
Do you know which countries have the highest longevity? How about the U.S. state where people live the longest, on average? Test your know-how with this WSJ quiz.
TWSJ·4h ago·3 min read
Health
J&J falls despite a beat-and-raise quarter. Why we’re raising our price target anyways
CNBC·18h ago·3 min read